Synthesis, radiolabeling and in vitro and in vivo characterization of a technetium-99m-labeled alpha-M2 peptide as a tumor imaging agent

Journal of Peptide Research

Volumn 63, Issue 6, 2004, Pages 460-468

  Okarvi, S M ^a  

^a KING FAISAL SPECIALIST HOSPITAL AND RESEARCH CENTER   (Saudi Arabia)

Author keywords

M2 peptide; Radiolabeling; Technetium 99m; Tumor imaging agent

Indexed keywords

CHELATE; MERTIATIDE TC 99M; PEPTIDE ALPHA M2; RADIOPHARMACEUTICAL AGENT; SYNTHETIC PEPTIDE; TECHNETIUM 99M; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CELL ACTIVITY; CELL STRAIN; CELL STRAIN MCF 7; DIAGNOSTIC IMAGING; DRUG DISTRIBUTION; EXPERIMENTAL MOUSE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; ISOTOPE LABELING; MOUSE; NONHUMAN; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; RADIOCHEMISTRY; SOLID; STATISTICAL SIGNIFICANCE;

AMINO ACID SEQUENCE; ANIMALS; BREAST NEOPLASMS; CELL LINE, TUMOR; FEMALE; HUMANS; MALE; MICE; MOLECULAR SEQUENCE DATA; ORGANOTECHNETIUM COMPOUNDS; PEPTIDES; RADIOPHARMACEUTICALS; TECHNETIUM;

ANIMALIA; MINK CELL FOCUS-FORMING VIRUS;

EID: 3042552354     PISSN: 1397002X     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1399-3011.2004.00160.x     Document Type: Article

References (19)

1. Okarvi, S.M. (2004) Peptide-based radiopharmaceuticals: future tools for diagnostic imaging of cancers and other diseases. Med. Res. Rev. 24, 357-397.
2. 99mTc-labelled peptide-based radiopharmaceuticals: an overview. Nucl. Med. Commun. 20, 1093-1112.
3. Fischman, A.J., Babich, J.W. & Strauss, H.W. (1993) A ticket to ride: peptide radiopharmaceuticals. J. Nucl. Med. 34, 2253-2263.
4. Blok, D., Feitsma, R.I.J., Vermeij, P. & Pauwels, E.J.K. (1999) Peptide radiopharmaceuticals in nuclear medicine. Eur. J. Nucl. Med. 26, 1511-1519.
5. Sivolapenko, G.B., Douli, V., Pectasides, D., Skarlos, D., Sirmalis, G., Hussain, R., Cook, J., Courtenay-Luck, N.S., Merkouri, E., Konstantinides, K. & Epenetos, A.A. (1995) Breast cancer imaging with radiolabelled peptide from complementarity-determining region of antitumor antibody. Lancet 346, 1662-1666.
6. Hussain, R., Courtenay-Luck, N.S., Siligardi, G. (1996) Structure-function correlation and biostability of antibody CDR-derived peptides as tumor imaging agents. Biomed. Pept. Prot. Nucl. Acids 2, 67-70.
7. Fiorenza, M., Prisco, G., Bartolomei, M., Chinol, M., Cremonesi, M., Leonardi, L., De Cicco, C. & Paganelli, G. (1997) Acquisition protocol for breast cancer imaging with technetium-99m-labeled synthetic peptide and technetium-99m-MDP. J. Nucl. Med. Technol. 25, 191-194.
8. 99mTc-labeled small peptides as diagnostic radiopharmaceuticals. Chem. Rev. 99, 2235-2268.
9. Seki, I., Itaya, Y., Hanaoka, K., Yoshida, Y., Shirakami, M. & Kato-Azuma, M. (1999) Technetium-99m chelating amino acid sequence for peptide labelling. In: Technetium, Rhenium and other Metals in Chemistry and Nuclear Medicine 5 (Nicolini, M. & Mazzi, U., eds), pp. 419-426. SGEditoriali, Padova.
10. Lister-James, J., McBride, W.J., Buttram, S., Civitello, E.R., Martel, L.J., Pearson, D.A., Wilson, D.M. & Dean, R.T. (1995) Technetium-99m chelate-containing receptor-binding peptides. In: Technetium, Rhenium and other Metals in Chemistry and Nuclear Medicine 4 (Nicolini, M. & Mazzi, U., eds), pp. 269-274. SGEditoriali, Padova.
11. Mather, S.J., Ellison, D., Bard, D.S. (1995) Technetium-99m labelled hybrid receptor-binding peptides. In: Technetium, Rhenium and other Metals in Chemistry and Nuclear Medicine4 (Nicolini, M. & Mazzi, U., eds), pp. 491-497. SGEditoriali, Padova.
12. Okarvi, S.M. & Al-Jammaz, I. (2003) Synthesis, radiolabelling and biological characteristics of a bombesin peptide analog as a tumor imaging agent. Anticancer Res. 23, 2745-2750.
13. 3 and biodistribution of by-products. Appl. Radiat. Isot. 39, 121-129.
14. Fukuoka, M., Kiyohara, T., Kobayashi, T., Kojima, A., Tanaka, A. & Kubodera, A. (1995) Synthesis and preclinical evaluation of technetium-99m- labeled hippurate analogues. Nucl. Med. Biol. 22, 181-191.
15. Barbarics, E., Kronauge, J.F., Davison, A. & Jones, A.G. (1998) Uptake of cationic technetium complexes in cultured human carcinoma cells and human xenografts. Nucl. Med. Biol. 27, 667-673.
16. García-Garayoa, E., Allemann-Tannahill, L., Bläuenstein, P., Willmann, M., Carrel-Rémy, N., Tourwé, D., Iterbeke, K., Conrath, P. & Schubiger, P.A. (2001) In vitro and in vivo evaluation of new radiolabeled neurotensin (8-13) analogues with high affinity for NT1 receptors. Nucl. Med. Biol. 28, 75-84.
17. Fields, G.B. & Noble, R.L. (1990) Solid phase peptide synthesis utilizing 9-fluorenylmethoxycarbonyl amino acids. Int. J. Pept. Prot. Res. 35, 161-214.
18. Okarvi, S.M., Adriaens, P. & Verbruggen, A. (1997) Comparison of the labelling characteristics of mercaptoacetyltriglycine (MAG3) with different S-protective groups. J. Label. Compds Radiopharm. 39, 853-874.
19. Van de Wiele, C., Dumont, F., Broecke, R.V., Oosterlinck, W., Cocquyt, V., Serreyn, R., Peers, S., Thornback, J., Slegers, G. & Dierckx, R.A. (2000) Technetium-99m RP527, a GRP analogue for visualisation of GRP receptor-expressing malignancies: a feasibility study. Eur. J. Nucl. Med. 27, 1694-1699.